Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
'We are pleased to have regained compliance with Nasdaq's minimum bid price requirement,' said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. 'This reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders.'
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.
Forward-Looking Statements
This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as 'will,' 'anticipate,' 'estimate,' 'expect,' 'plan,' 'should,' and 'may' and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to maintain compliance with Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our ability to use the latest technology to support our commercialization efforts; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings which are available on the SEC's website at www.sec.gov.
Investor Contact:Ilanit AllenVP, Corporate Communications & Investor RelationsCitius Pharmaceuticals, Inc.ir@citiuspharma.com908-967-6677 ext. 113
Media Contact:Greg SalsburgSTiR-communicationsGreg@STiR-communications.com908-967-6677 ext. 113
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
3 hours ago
- The Sun
Wall Street stocks dip as chip sector reacts to China revenue-sharing deal
WALL STREET'S main indexes were down on Monday as investors await inflation data this week and chip companies seesawed after agreeing to share a portion of revenue from China sales with the U.S. under a trade policy shift from the Trump administration. Nvidia was flat after reversing premarket losses, and Advanced Micro Devices was up 0.5% in volatile trading. A U.S. official told Reuters the semiconductor majors had agreed to give the United States government 15% of revenue from sales of their advanced chips to China. Analysts said the levy could hit the chipmakers' margins and set a precedent for Washington to tax critical U.S. exports, potentially extending beyond semiconductors. 'A lot of people are not sure what to make of that because this is the first time in history that it's ever happened where an administration wants a percentage of the profits from a publicly traded company,' said Michael Matousek, head trader at U.S. Global Investors. Enabling semiconductor sales to China was an integral issue in the agreement Washington and Beijing signed this year, which expires on Tuesday. U.S. President Donald Trump lauded China's cooperation in talks at a White House press conference on Monday. At 2:01 p.m. ET (1801 GMT), the Dow Jones Industrial Average fell 176.88 points, or 0.40%, to 43,998.91, the S&P 500 lost 5.60 points, or 0.09%, to 6,383.93, and the Nasdaq Composite lost 12.87 points, or 0.06%, to 21,437.15. Traders took a step back after the S&P 500 and the Nasdaq last week logged their strongest weekly performances in more than a month. On Monday, the tech-heavy Nasdaq was on track for its third consecutive record closing high, if gains hold. Investors expect the recent shakeup at the U.S. Federal Reserve and signs of labor market weakness could nudge the central bank into adopting a dovish monetary policy stance later this year, fueling much of the optimism. July's consumer inflation report is due on Tuesday, and investors anticipate that the Fed will lower borrowing costs by about 60 basis points by December, according to data compiled by LSEG. 'Markets are on rate watch, so anything inflation-related will move markets this week,' said Jamie Cox, managing partner at Harris Financial Group. 'It's all about three rate cuts versus two at this point.' Citigroup and UBS Global Research became the latest brokerages to raise their year-end targets for the benchmark S&P 500. Micron Technology raised its forecast for fourth-quarter revenue and adjusted profit, boosting its shares 3%. Intel was up 3.5% after a report said CEO Lip-Bu Tan was expected to visit the White House. Trump had called for his removal last week. TKO jumped 8.5% after Paramount bought the rights from the live entertainment company to exclusively distribute UFC events for the next seven years in a deal valued at around $7.7 billion. Trump is expected to meet Russia's President Vladimir Putin on Friday to try and negotiate an end to Russia's war on Ukraine. Declining issues outnumbered advancers by a 1.11-to-1 ratio on the New York Stock Exchange. There were 203 new highs and 89 new lows on the NYSE. On the Nasdaq, declining issues outnumbered advancers by a 1.12-to-1 ratio. The S&P 500 posted 14 new 52-week highs and 15 new lows, while the Nasdaq Composite recorded 65 new highs and 98 new lows. - Reuters
New Straits Times
a day ago
- New Straits Times
MCE eyes growth on Perodua EV, US expansion: HLIB
KUALA LUMPUR: MCE Holdings Bhd is set to enter a multi-year growth phase on the back of a landmark Perodua electric vehicle (EV) contract and expansion into the United States, according to Hong Leong Investment Bank (HLIB) Research. HLIB Research has initiated coverage on MCE with a "Buy" call and a target price of RM2.40, valuing the stock at 15 times its mid-FY27 partially diluted earnings per share of 16 sen. The firm described the auto parts supplier as a resilient, scalable play on Malaysia's shift towards high-value automotive electronics and the global 'China + N' supply chain realignment. MCE's entry into the EV segment comes through a high-value contract with Perodua to supply infotainment and advanced driver assistance system (ADAS) components, with revenue per vehicle at around RM3,000, about ten times its typical value. "With Perodua targeting an affordable launch price, we estimate MCE's annual revenue from this programme could amount to between RM39.8 million and RM59.7 million annually, or 26 per cent to 38 per cent of FY24 revenue, making it a powerful earnings catalyst," HLIB Research said. HLIB Research added that the company is accelerating its global expansion with two US wins for Nasdaq-listed Dorman in the automotive aftermarket and Michigan-based JVIS, a supplier to major original equipment manufacturers. The firm said the JVIS deal involves two multi-year mechatronics supply contracts worth RM91.7 million over five years, adding about RM18.3 million annually. Beyond automotive, MCE is expanding into new growth areas via multiple joint ventures, including a tie-up with Hong Kong's Sounding Industries to produce non-automotive products at its Johor facilities. The company also partnered with China's Nanjing Chuhang to produce ADAS mmWave radars at its upcoming Serendah plant, along with Chery-linked suppliers Cheling and Atech for participation in Chery's Malaysian localisation programme. MCE also formed a joint venture with India's Abhishek Electronics to tap into the fast-growing Indian automotive market. HLIB Research projects MCE's core earnings to grow at a compound annual growth rate of 15.8 per cent with estimated earnings for FY25, FY26 and FY27 reaching RM20.2 million, RM21.4 million and RM27 million, respectively. "FY26 growth will be driven by contribution from Dorman and the non-auto segment starting in the first half of FY26, with a stronger lift in the second half from Perodua's EV supply. "FY27 will see the full-year EV impact, maiden JVIS contribution and scaling of Dorman and non-auto has a robust balance sheet with a net cash position of RM83.6 million, equivalent to 59.8 sen a share, around 42 per cent of market capitalisation," the firm added. HLIB Research said years of investment in engineering and technology now position MCE to ride structural shifts in Malaysia's automotive industry towards localisation, high-value electronics and EV adoption, while benefiting from global supply chain diversification. It added that the company offers a resilient, scalable play on the sector's long-term transformation, anchored by stable demand from Proton and Perodua, as well as expansion via high-margin electronics, exports and strategic JVs.
New Straits Times
a day ago
- New Straits Times
Shares edge up in Asia, US inflation data looms large
SYDNEY: Major share indexes crept higher in Asia on Monday as upbeat company earnings underpinned high valuations in the tech sector, while a crucial report on US inflation would likely set the course of the dollar and bonds. Trade and geopolitics also loom large with a US tariff deadline on China due to expire on Tuesday amid expectations it will get extended again, while President Donald Trump and Russian leader Vladimir Putin are due to meet in Alaska on Friday to discuss Ukraine. The main economic release will be US consumer prices on Tuesday, with analysts expecting the impact of tariffs to help nudge the core up 0.3 per cent to an annual pace of 3.00 per cent and away from the Federal Reserve target of 2.00 per cent. An upside surprise would challenge market wagers for a September rate cut, though analysts assume it would have to be a very high number given a downward turn in payrolls is now dominating the outlook. "The tone from the Fed has shifted as a number of officials expressed concerns about growth following the July employment report," said Bruce Kasman, chief economist at JPMorgan. "We now expect the Fed to restart its easing cycle in September," he added. "Recession risks are elevated at 40 per cent, but we do not yet see a case for a larger than 25bp series of cuts." Markets imply around a 90 per cent probability of a September easing, and at least one more cut by year end. Trump's pick for Fed governor, Stephen Miran, may or may not be in place in time to vote for a cut in September, while the choice of a new chair has broadened out to around 10 contenders. The prospect of lower borrowing costs has supported equities, along with a run of strong earnings. Analysts at BofA note 73 per cent of companies had beaten on earnings, well above the 59 per cent long run average, while 78 per cent beat on revenue. "While mentions of 'weak demand' ticked up and tariff concerns remain, corporate sentiment and guidance are improving," they said in a note. S&P 500 futures and Nasdaq futures both edged up 0.1 per cent to near record highs. Analysts were unsure what to make of a report in the Financial Times that tech majors Nvidia and AMD have agreed to give the US government 15 per cent of their revenues from chip sales in China, under an arrangement to obtain export licences for the semiconductors. Japan's stock market was closed for a holiday, but futures stood at 42,290 and well above the cash close of 41,820, suggesting the index could test its all-time high of 42,426 this week. MSCI's broadest index of Asia-Pacific shares outside Japan was a fraction firmer, while South Korea was flat having bounced 2.9 per cent last week. EUROSTOXX 50 futures added 0.2 per cent, while FTSE futures were flat and DAX futures firmed 0.3 per cent. Currencies were quiet with markets thinned by Japan's absence, with the dollar index steady at 98.246 after slipping 0.4 per cent last week. The euro was flat at US$1.1644 and comfortably above its recent trough of US$1.1392, while the dollar held at 147.66 yen having met resistance around 147.90. The Australian dollar eased to US$0.6516 ahead of a meeting of the Reserve Bank of Australia which is widely expected to sanction a rate cut, having stunned markets in July by skipping an easing to await more inflation data. The figures turned out benign, so investors have again fully priced a quarter-point cut to 3.60 per cent. In commodity markets, gold dipped 0.3 per cent to US$3,386.00 an ounce after wild swings last week on reports the US would slap 39 per cent tariffs on some gold bars, which are major exports of Switzerland. Gold futures pared gains on Friday when the White House said it planned to issue an executive order clarifying the country's stance on gold bar tariffs. Oil prices slipped amid risks the talks between Trump and Putin could make progress to a ceasefire in Ukraine and possibly an eventual easing of sanctions on Russian oil exports. Brent dropped 0.6 per cent to US$66.22 a barrel, while US crude eased 0.7 per cent to US$63.44 per barrel.
